Abstract:Background/Objectives: Estrogen receptor-α coactivator MED1 is overexpressed in 40–60% of human breast cancers, and its high expression correlates with poor disease-free survival of patients undergoing anti-estrogen therapy. However, the molecular mechanism underlying MED1 upregulation and activation in breast cancer treatment resistance remains elusive. Methods: miRNA and mRNA expression analysis was performed using the NCBI GEO database. MED1 targeting and its impact on therapy resistance was evaluated in control and tamoxifen-resistant breast cancer cell lines by miR-205 overexpression and inhibition. Immunoblotting, chromatin immunoprecipitation, and luciferase reporter assays were used to understand the molecular mechanism of MED1-mediated tamoxifen resistance. Mice xenograft models were used to validate treatment efficacy and molecular mechanisms in vivo. Results: miR-205 was found to directly target and suppress the expression of MED1 through bioinformatic analyses and experimental validations. An inverse correlation of miR-205 and MED1 was observed in breast cancer patients with high MED1/low miR-205, indicative of poor prognosis in long-term anti-estrogen treatment. Furthermore, the depletion of miR-205 was observed in tamoxifen-resistant breast cancer cells overexpressing MED1. The restoration of miR-205 expression attenuated MED1 expression and re-sensitized cells to tamoxifen both in vitro and in vivo. Interestingly, miR205 was also found to target another key regulatory gene, HER3, which drives PI3K/Akt signaling and MED1 activation by phosphorylation. Importantly, we found ER target gene transcription and promoter cofactor recruitment by tamoxifen can be reversed by induced miR205 expression. Conclusions: Altogether, miR-205 functions as a negative regulator of MED1 and HER3, affecting the regulation of the HER3-PI3K/Akt-MED1 axis in anti-estrogen resistance, and could serve as a potential therapeutic regime to overcome treatment resistance.

HER2-Driven Breast Tumorigenesis Relies Upon Interactions of the Estrogen Receptor with Coactivator MED1.

Functional Cooperation Between Co-Amplified Genes Promotes Aggressive Phenotypes of HER2-positive Breast Cancer.

Essential role of MED1 in the transcriptional regulation of ER-dependent oncogenic miRNAs in breast cancer

Key Roles for Med1 Lxxll Motifs in Pubertal Mammary Gland Development and Luminal-Cell Differentiation

HER2 Phosphorylation Induced by TGF-β Promotes Mammary Morphogenesis and Breast Cancer Progression.

MED1 induces M2 polarization of tumor-associated macrophages to aggravate breast cancer

miR-205 Regulates Tamoxifen Resistance by Targeting Estrogen Receptor Coactivator MED1 in Human Breast Cancer

Caveolin-1 Down-Regulation Activates Estrogen Receptor Alpha Expression and Leads to 17 Beta-Estradiol-Stimulated Mammary Tumorigenesis

Arginine and Glutamate-rich 1 (ARGLU1) Interacts with Mediator Subunit 1 (MED1) and is Required for Estrogen Receptor-mediated Gene Transcription and Breast Cancer Cell Growth

Mediator of ERBB2-driven Cell Motility (MEMO) Promotes Extranuclear Estrogen Receptor Signaling Involving the Growth Factor Receptors IGF1R and ERBB2,

Silencing Med1 Sensitizes Breast Cancer Cells To Pure Anti-Estrogen Fulvestrant In Vitro And In Vivo

MUC1 Triggers Lineage Plasticity of Her2 Positive Mammary Tumors

A Role of Estrogen/erα Signaling in BRCA1-associated Tissue-Specific Tumor Formation

MEDAG enhances breast cancer progression and reduces epirubicin sensitivity through the AKT/AMPK/mTOR pathway

Identification of A Novel Estrogen Receptor Beta 1 Binding Partner, Inhibitor of Differentiation-1, and Role of Er Beta 1 in Human Breast Cancer Cells

Pparγ1 Facilitates ErbB2-Mammary Adenocarcinoma in Mice

HER2-intronic miR-4728-5p facilitates HER2 expression and accelerates cell proliferation and migration by targeting EBP1 in breast cancer

Estrogen Receptor Α-Coupled Bmi1 Regulation Pathway in Breast Cancer and Its Clinical Implications

HER-2 promotes breast cancer cell epithelial-mesenchymal transition by regulating ZEB1

Developmental Stage Determines Estrogen Receptor Alpha Expression and Non-Genomic Mechanisms That Control IGF-1 Signaling and Mammary Proliferation in Mice.

A role of estrogen|[sol]|ER|[alpha]| signaling in BRCA1-associated tissue-specific tumor formation